Mediators of inflammation · 2026
Propofol and Salvianolic Acid a Synergistically Attenuate LPS-Induced Myocardial Pyroptosis in Diabetic Mice via the SIRT1/HMGB1 Pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Anyuan, Han Ronghui, Han Kaijia, Li Ting, Zhu Jianyu, Wang Yongyan, Zhou Jiaqi, Chen Jiajia, Shangguan Wangning, Wong Stanley Sau Ching, Xia Weiyi, Chen Guanghua, Xia Zhengyuan
Аннотация
BACKGROUND: We investigated whether propofol (PPF) combined with salvianolic acid A (SAA) confers synergistic cardioprotection in diabetic sepsis.
METHODS: Diabetic-septic mice and high-glucose/LPS-treated cardiomyocytes were treated with PPF and SAA. Cardiac function, reactive oxygen species (ROS), inflammation, and the SIRT1/HMGB1 pathway were assessed.
RESULTS: PPF combined with SAA synergistically attenuated cardiac inflammation, pyroptosis, and dysfunction, accompanied by SIRT1 upregulation and HMGB1 downregulation. Notably, low-dose coadministration of PPF (12.5 µM) and SAA (12.5 µM) achieved protection comparable to high-dose PPF (25 µM), significantly reducing ROS and pyroptosis markers. These protective effects were reversed by SIRT1 inhibition or silencing but enhanced by HMGB1 inhibition.
CONCLUSION: PPF and SAA synergistically inhibit LPS-induced myocardial pyroptosis under hyperglycemia by activating the SIRT1/HMGB1 pathway. This combination offers a potential strategy to enhance cardioprotection while minimizing anesthetic dosage.
METHODS: Diabetic-septic mice and high-glucose/LPS-treated cardiomyocytes were treated with PPF and SAA. Cardiac function, reactive oxygen species (ROS), inflammation, and the SIRT1/HMGB1 pathway were assessed.
RESULTS: PPF combined with SAA synergistically attenuated cardiac inflammation, pyroptosis, and dysfunction, accompanied by SIRT1 upregulation and HMGB1 downregulation. Notably, low-dose coadministration of PPF (12.5 µM) and SAA (12.5 µM) achieved protection comparable to high-dose PPF (25 µM), significantly reducing ROS and pyroptosis markers. These protective effects were reversed by SIRT1 inhibition or silencing but enhanced by HMGB1 inhibition.
CONCLUSION: PPF and SAA synergistically inhibit LPS-induced myocardial pyroptosis under hyperglycemia by activating the SIRT1/HMGB1 pathway. This combination offers a potential strategy to enhance cardioprotection while minimizing anesthetic dosage.